A TRADE FRAMEWORK FOR INTELLECTUAL PROPERTY RIGHTS, EQUITY PRICING AND MARKET SEGMENTATION Juan Rovira The World Bank Health, Nutrition and Population.

Slides:



Advertisements
Similar presentations
THE CHALLENGES & OPORTUNITIES OF ACCESS TO MEDICINES IN AFRICA Dr Pascoal MOCUMBI, orig Mozambique,High Representative EDCTP ABRASCO/WFPHA.
Advertisements

MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Differential Pricing: Reconciling R&D, IP and Access Patricia M. Danzon PhD The Wharton School University of Pennsylvania.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Consultative expert working group - proposals Barcelona
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
AMAP BDS: A VALUE CHAIN FRAMEWORK FOR PROMOTING ECONOMIC GROWTH THAT REDUCES POVERTY JEANNE DOWNING 7/28/05.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
1 Strategic choice of financing systems in regulated and interconnected industries Anna BassaniniJerome Pouyet Rome & IDEICREST-LEI & CERAS-ENPC
Jean O. Lanjouw February, 2003 The Global Patent System and the Availability of Pharmaceuticals in Poor Countries.
©2013 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
The World Public Health at a Crossroad Guillermo Foladori CSPO Columbia University 2003 Meeting “The Uneven Evolution of Medical Know-how” Burden Room,
Where Does Level of Development Vary by Gender?
EMAS III: A mature instrument for new challenges Soledad BLANCO Director, Directorate Industry DG Environment.
1 Problems of measurement and analysis in the national accounts under rapidly growing globalization. Soli Peleg Central Bureau of Statistics, Israel.
Global Competitiveness Report 2013/14 Suriname. The Global Competitive Report The GCR is produced by the World Economic Forum The report is based on the.
International Organizations. The United Nations (UN) The United Nations was created on October 24, countries made up the original United Nations.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
PANAMA PANAMA WHAT NEEDS TO BE DONE TO MAKE IT A HIGH GROWTH ECONOMY January 27, 2005.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
A Common Immigration Policy for Europe Principles, actions and tools June 2008.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.
Influence of foreign direct investment on macroeconomic stability Presenter: Governor CBBH: Kemal Kozarić.
3 August 2004 Public Health Practice III: FINANCING PUBLIC HEALTH REFORM Thomas E. Novotny MD MPH University of California San Francisco Institute for.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
Presentation on the topic Globalization Privatization Liberalization
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
COMPETITION IN THE MARKETPLACE. BUYERS & SELLERS  BUYERS = CONSUMERS  SELLERS = PRODUCERS BUYERS & SELLERS COME TOGETHER TO EXCHANGE THINGS OF VALUE.
Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“
1 Determining Value for Innovation and Setting Prices Richard Laing EDM/PAR WHO.
DISCOVERY HEALTH COMMENTS ON THE MEDICINES AND RELATED SUBSTANCES BILL August 2008.
Ellen ‘t Hoen Médecins sans Frontières
Pathways out of Poverty Can R&D help small-scale producers benefit from coordinated supply chains? Can R&D help small-scale producers benefit from coordinated.
The role of the state and development Intro. – State before and after Washington Consensus – New Consensus – Recent theories of Development policy formation,
Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.
Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.
DEFINING THE DEVELOPING WORLD ECONOMIC DEVELOPMENT.
Eastern Europe and Central Asia: Economic Outlook and Challenges Ahead ISTANBUL CHAMBER OF INDUSTRY - 6th INDUSTY CONGRESS November , 2007 Klaus.
Private Sector Development Efficiency, Productivity and Growth 1 Development Equity Associates Inc. February-March, Sources: World Bank 2003;
International Trade Chapter #4.
Where one grows their own food and makes their own goods. Trade amongst others to obtain what they need. Mostly in remote areas.
© dreamstime CLIMATE CHANGE 2014 Mitigation of Climate Change Working Group III contribution to the IPCC Fifth Assessment Report.
Overview of China’s health care reform Wen Chen, Ph.D., Professor Fudan School of Public Health March 21, 2016.
Economics The Economic Problem Scarcity Absolute & Comparative Advantage Opportunity Cost Economic Systems Free Trade v. Protectionism v. Fair Trade.
Capacity Building within CARIFORUM on Competition Policy David Miller – Executive Director May 5, 2016 Promoting competitive markets FAIR TRADING COMMISSION.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
“…global multinationals have … viewed developing Asia [countries]…as an offshore-production platform. The offshore- efficiency solution is still an attractive.
EXTERNAL INFLUENCES These are factors that the business can not control (External constraints) PESTEL Analysis is a part of the external analysis that.
Market Failure and Government Intervention
A Fiscal Insurance Scheme for the Eastern Caribbean Currency Union
Global Economic Trends and the 2030 Development Agenda
International Trade.
Imperfect Competition and International Trade
Free Trade vs Protectionism, That is the Question
Efficiency and Equity in a Competitive Market
Carnegie Institution of Washington
Operations Management Introduction to operations Management 1.
Obligation to contribute to R&D costs Use of pharmaceutical inventions without authorization of patent owners James Love. CPTech 16 April 2004 Twelfth.
Lifelong Learning in the Global Knowledge Economy
SACF Comments on the ECA Amendment Bill B
COMPETITION POLICY AND IP
Decent Work in the Americas:
Access to Essential Medicines
Presentation transcript:

A TRADE FRAMEWORK FOR INTELLECTUAL PROPERTY RIGHTS, EQUITY PRICING AND MARKET SEGMENTATION Juan Rovira The World Bank Health, Nutrition and Population

TWO APPROACHES FOR MAKING DRUGS AFFORDABLE TO LOW INCOME POPULATIONS 1. Single price and (cross)subsidies to the poor 2. Equity pricing Within countries and across countries

WHAT IS MENT BY EQUITY PRICING? A price structure where prices for each market segment (population group) are lower, the lower the economic capacity of the segment By extension, the arrangement leading to the defined price structure Not to be identify with Ramsey pricing Differential, preferential, tiered pricing?

RATIONALE FOR EQUITY PRICING It potentially is a win-win solution for funding a global public good: therapeutic innovation Patent holders obtain a higher share of the consumer surplus than under a single international price scenario (although probably less than under a Ramsey pricing approach). Consumers (even in richer countries) benefit as well from likely larger R+D

APPROACHES TO EQUITY PRICING 1.Centralized production by the patent holder or originator, charging different effective prices 2.Tiered royalties and multiple producers Option 1 makes control of quality and diversion probably easier. It can be seen as a form of unfair competition, that may inhibit industrial development in low income countries. Option 2 promotes industrialization in developing countries and generic competition. However, it may not lead to low prices if there is no competition in the respective markets.

IMPLEMENTATION OF EQUITY PRICING Selection of products individually decided by patent holders on a voluntary basis. There should, however, be a commitment to transparency and to sustainability, e.g. by setting maximum prices in the lower price segments, as a stable percentage of the price in the high price segment. Buyers should be allowed to use existing tools in order to further reduce the effective price

MARKET SEGMENTATION Market segmentation or separability is a necessary condition for any type of significant price differentials, such as those envisaged in equity pricing proposals

MARKET SEGMENTATION OPTIONS Two or more segments? Criterion: economic capacity, burden of disease? Indicator: GNP per capita? How are tiered prices/royalties set and updated

EXISTING COUNTRY CATEGORIZATIONS (1) World Bank. World Development Reports: 1.Low income (GNP per capita of US$ 755 or less) 2.Lower-middle income (US$ 756-2,995) 3.Upper-middle-income (US$ 2,996-9,265) 4.High income (US$ 9,266 or more) Source: Europe Economics. Medicines Access and Innovation in Developing Countries, September 2001.

EXISTING COUNTRY CATEGORIZATIONS (2) UN. World Economic and Social Surveys: developed economies, economies in transition and developing countries (includes as a subcategory, LDC) IMF. World Economic Outlook: advanced economies, developing economies, economies in transition. UNICEF. Global access to vaccines: A, countries in need of financial support; B, Countries for which support should be moderate; C, Countries becoming rapidly independent; D, Self-sufficient countries

EXISTING COUNTRY CATEGORIZATIONS (3) UNIDO. State of the pharmaceutical industry (Criterion: type of prevalent pharmaceutical firms): 1.A, Sophisticated PI (pharmaceutical industry) and significant research base; 2.B, PI with innovative capacity; 3.C, PI with reproductive capacity; 4.D, no PI

PRODUCT FLOWS IN THE PROPOSED MODEL OF MARKET SEGMENTATION O O O O HIGH INCOME CONTRIES INTERMEDIATE INCOME COUNTRIES LOW INCOME COUNTRIES

WHAT ARE THE OBSTACLES TO MARKET SEGMENTATION (SEPARABILITY) Low priced drugs in developing countries suffer fatal attraction from high price countries. Potential beneficiaries are not only parallel traders, but also consumers, providers and insurers in developed countries and industry and treasury in exporting countries. Accessibility problems in developed countries. Belief of the urbi et orbi goodness of free markets in spite of market failures (also know as market fundamentalism). May be honest or interested.

WHAT CAN BE DONE TO ENSURE SEGMENTATION? Industry: Physical differentiation of products aimed at each segment Developed countries: Use legislation, sanctions and control in order to prevent improper imports Developing countries: Use legislation, sanctions and control in order to prevent improper exports International organizations, consumer associations, etc: support and legitimize market segmentation for equity pricing

EQUITY PRICING IS NOT THE PANACEA! It is only a way to address some market and policy failures, but it does not solve: Financial and physicals constraints The problem of neglected diseases The questionable goals and efficiency of how R+D and innovation is currently done Other sources of monopolistic power and market failures BUT IT MAY BE A GREAT STEP FORWARD !